SOFINNOVA
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced that Noema Pharma (“Noema”), has raised an oversubscribed CHF 103 million (approx. USD 112 million) Series B financing round. Sofinnova co-founded and seed financed Noema in 2019 with Dr. George Garibaldi and Luigi Costa. The company was established to advance clinical stage assets in-licensed from Roche.
Noema is a clinical-stage biopharmaceutical company focused on central nervous system disorders. Existing investors Sofinnova Partners, Polaris Partners, Gilde Healthcare and Invus welcomed new investors Forbion and Jeito Capital, as well as UPMC Enterprises and another undisclosed investor.
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets, including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor that is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC). The company is also developing gemlopodect (NOE-105), a PDE10a inhibitor being evaluated in Phase 2b clinical trials for Tourette Syndrome and Childhood Onset Fluency Disorder (COFD) or Stuttering; and NOE-115, a Phase 2 ready triple reuptake inhibitor for Atypical Depression and Binge Eating Disorder.
Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners, said: “As co-founders and initial investors of Noema, we are incredibly proud of what the company has accomplished since its inception. Raising an oversubscribed funding round of this magnitude is a significant achievement that further reinforces our conviction that Noema can make a meaningful difference in the lives of patients suffering from debilitating CNS disorders. Noema is the perfect illustration of our core strategy and expertise: we nurture innovative companies centered on groundbreaking science and exceptional talent that have the potential to deliver transformative results for patients.”
Luigi Costa, Chief Executive Officer of Noema Pharma, said: "We are excited to announce the successful completion of this oversubscribed Series B financing round and very pleased to have a world-class group of investors supporting our vision of bringing much-needed treatments to those living with debilitating central nervous system disorders. This financing comes at a key time for Noema Pharma as we look forward to extensive news flow over the next 24 months.”
The Series B financing follows a CHF 54 million (approx. USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners. Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.
About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. The firm actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners has over €2.5 billion under management. For more information, please visit: sofinnovapartners.com.
About Noema Pharma
Noema Pharma (www.noemapharma.com) is a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks. The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche. Noema currently has 3 active Phase 2b clinical trials in highly undertreated CNS conditions: seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia and Childhood Onset Fluency Disorder. The Company has completed a Phase 2a clinical trial in adult patients with Tourette Syndrome that is currently being extended with an adolescent cohort. The Company has also completed preclinical validation studies in Atypical Depression and Binge Eating Disorder. Noema Pharma was founded in 2019 by the leading venture capital firm Sofinnova Partners. Additional investors include Biomed Partners, Forbion, Gilde Healthcare, Invus, Jeito Capital, Polaris Partners, UPMC Enterprises, and an undisclosed investor.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005296/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Green Street Expands Private Market Coverage with European Self-Storage Data and Analytics13.5.2025 10:00:00 CEST | Press release
Firm releases comprehensive macro insights into the European self-storage sector, via its latest Outlook report Green Street, the foremost provider of commercial real estate intelligence and insights, has expanded its private market research coverage to the European self-storage sector. Utilising 5 years of forecasted insights and 10 years of historical data, Green Street’s new Self-Storage Outlook focuses on investment opportunities available in 30 European cities. “Living quarters are becoming more compact and storage space is being cut back in urban developments, necessitating off-premises storage solutions for residential occupiers. Additionally, approximately 40% of the business customer base consists of small-to-medium-sized entities, particularly online retailers in the region,” said Marie Dormeuil, Head of European Market Analytics. “The growth in real spending on storable goods is expected to increase at 2% per annum over the next five years, supporting healthy demand growth.”
Oracle and Infobip Enhance Partnership to Deliver Global Conversational Experiences13.5.2025 10:00:00 CEST | Press release
Global cloud communications platform Infobip today announced that it has enhanced its partnership with Oracle to bring conversational experiences to businesses and brands globally. The new integration enables Infobip and Oracle customers and partners to access Infobip's omnichannel services through Oracle Integration. Customers increasingly expect omnichannel communications, but integrating and managing new channels can be time-consuming, requiring complex development, deployment, and organizational processes. Infobip’s new Omnichannel Messaging Adapter for Oracle Integration addresses this challenge byenabling all types of businesses to work with and manage omnichannel messaging channels involving Oracle and third-party solutions, including WhatsApp and RCS. The solution deploys quickly, reducing time to market. In addition, Infobip has provided a prebuilt use case – or Accelerator – for Oracle’s contact center solution, Oracle B2C Service. This Accelerator is a flexible solution that
Galeria Teams Up With Blue Yonder to Enhance the In-Store and Online Customer Shopping Experience13.5.2025 10:00:00 CEST | Press release
Germany's iconic department store chain deploys Blue Yonder’s AI-driven demand and replenishment capabilities to strengthen its commitment to quality and convenience In today's rapidly evolving retail landscape, consumers increasingly seek personalized shopping experiences tailored to meet their specific demand requirements. For omni-channel retailers, success depends on seamlessly delivering high-quality products and excellent customer service powered by advanced technology that effectively supports a demand-driven, omni-channel strategy. That is why Galeria, Germany´s leading department store chain, has chosen to deploy Blue Yonder’s demand and replenishment capabilities to strengthen its supply chain and enhance operational efficiency. This strategic investment enables the retailer to deliver a highly responsive and seamless shopping experience across both in-store and online channels, reinforcing Galeria's commitment to quality and convenience. Galeria previously relied mainly on m
SecurityBridge Teams up With Microsoft to Enhance SAP Security With Microsoft Sentinel13.5.2025 09:17:00 CEST | Press release
SecurityBridge, the Cybersecurity Command Center for SAP, is pleased to announce its collaboration with Microsoft to integrate SAP data into Microsoft Sentinel. The integration enables SecurityBridge to seamlessly share SAP security events with Microsoft Sentinel’s cloud-native security information and event management (SIEM)—enhancing the visibility to detect and respond to threats across SAP landscapes when it matters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513088279/en/ SecurityBridge x Microsoft Sentinel in action. "This close collaboration represents a significant advancement in SAP security. Combining our SAP-native cybersecurity platform with Microsoft Sentinel’s capabilities makes complex SAP security events accessible and actionable for all security teams, ultimately supplying customers with the knowledge to better secure SAP systems from threats," said Ivan Mans, CTO & Co-Founder, SecurityBridge. SAP sys
Saildrone Closes $60M Financing to Bring Maritime Autonomy to Europe13.5.2025 09:05:00 CEST | Press release
The new funding round, led by EIFO (Export and Investment Fund of Denmark), enables access to Saildrone’s unique maritime intelligence technology for critical European security and defense needs Saildrone, the global leader in maritime autonomy, today announced the closing of a $60 million investment round led by EIFO, the Export and Investment Fund of Denmark. The investment will be used to bring Saildrone technology to Europe to address the urgent need for maritime security for critical infrastructure and wider defense applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513296505/en/ Four Saildrone Voyager uncrewed surface vehicles (USVs) will be deployed in Danish waters during the summer of 2025 in partnership with the Danish Armed Forces. The operational testing will begin in June and is part of a broader effort to integrate uncrewed systems into Denmark’s defense architecture. The Baltic, North Sea, and Eur
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom